BioXcel Therapeutics faces regulatory challenges after the FDA found inconsistencies in one of its clinical trial sites, jeopardizing the supplementary approval of its drug, IGALMI. BioXcel's ...

By Michael Blake, Defense Opinion Writer. As artificial intelligence (AI) systems become deeply integrated into military ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. GenAI is also making a splash in software development and mobile applications. In fact, due ...

Throughput, efficiency, and reproducibility are key concerns in laboratory studies. Advances in digital science solutions and automated technologies are driving recent improvements in lab results, ...

A new research report from Yale School of Medicine offers an up-close look at how biased artificial intelligence can affect clinical outcomes. The study focuses specifically on the different stages of ...

Dmytro Lazarchuk is a cofounder and CEO of Relokia with over eight years of experience in digital marketing and data migration services. Annually, businesses waste $85 billion fixing technical ...

The present world of digital transformation, streamlining workflows, enhancing operational efficiencies, and eliminating paper demands connected workflows with fully integrated systems and equipment.

BioXcel Therapeutics (NASDAQ:BTAI) fell ~58% pre-market Thursday even after announcing that its Phase 3 trial for Alzheimer’s candidate BXCL501 reached its main goal as investors reacted to its data ...

Australian organisations have lost an average of A$493,000 over the past 12 months due to data integrity flaws, hampering their artificial intelligence (AI) ambitions and eroding their competitive ...

Fraud and misconduct continue apace in Alzheimer's research, undermining progress in understanding and treating the disease, say investigators who endeavor to expose errors and misleading practices.